Vatiquinone
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich Ataxia
Conditions
Friedreich Ataxia
Trial Timeline
Oct 12, 2022 → Aug 29, 2024
NCT ID
NCT05485987About Vatiquinone
Vatiquinone is a phase 2 stage product being developed by PTC Therapeutics for Friedreich Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT05485987. Target conditions include Friedreich Ataxia.
What happened to similar drugs?
0 of 9 similar drugs in Friedreich Ataxia were approved
Approved (0) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07159139 | Pre-clinical | Active |
| NCT05515536 | Phase 3 | Active |
| NCT05485987 | Phase 2 | Completed |
| NCT05218655 | Phase 3 | Completed |
| NCT04378075 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Friedreich Ataxia